151 related articles for article (PubMed ID: 6284643)
1. In vivo induction of anti-herpes simplex virus immune response by type 1 antigens and lipid A incorporated into liposomes.
Naylor PT; Larsen HS; Huang L; Rouse BT
Infect Immun; 1982 Jun; 36(3):1209-16. PubMed ID: 6284643
[TBL] [Abstract][Full Text] [Related]
2. Antibody responses, cytokine levels and protection of mice immunised with HSV-2 antigens formulated into NISV or ISCOM delivery systems.
Mohamedi SA; Brewer JM; Alexander J; Heath AW; Jennings R
Vaccine; 2000 Apr; 18(20):2083-94. PubMed ID: 10715522
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
J Virol; 2017 May; 91(9):. PubMed ID: 28228587
[TBL] [Abstract][Full Text] [Related]
4. Cell-mediated immunity to herpes simplex virus: induction of cytotoxic T lymphocyte responses by viral antigens incorporated into liposomes.
Lawman MJ; Naylor PT; Huang L; Courtney RJ; Rouse BT
J Immunol; 1981 Jan; 126(1):304-8. PubMed ID: 6969745
[TBL] [Abstract][Full Text] [Related]
5. Influence of peptide acylation, liposome incorporation, and synthetic immunomodulators on the immunogenicity of a 1-23 peptide of glycoprotein D of herpes simplex virus: implications for subunit vaccines.
Brynestad K; Babbit B; Huang L; Rouse BT
J Virol; 1990 Feb; 64(2):680-5. PubMed ID: 2153234
[TBL] [Abstract][Full Text] [Related]
6. Modified-self-induced modulation of the immune response to herpes simplex virus: effect on antibody formation, cytotoxic T lymphocyte induction, and survival.
Wilson LA; Karabin JM; Smith JW; Dawson D; Scott DW
J Immunol; 1984 Mar; 132(3):1522-8. PubMed ID: 6198395
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2.
Hazama M; Mayumi-Aono A; Asakawa N; Kuroda S; Hinuma S; Fujisawa Y
Vaccine; 1993; 11(6):629-36. PubMed ID: 8391739
[TBL] [Abstract][Full Text] [Related]
8. Helper T cells induced by an immunopurified herpes simplex virus type I (HSV-I) 115 kilodalton glycoprotein (gB) protect mice against HSV-I infection.
Chan WL; Lukig ML; Liew FY
J Exp Med; 1985 Oct; 162(4):1304-18. PubMed ID: 2995536
[TBL] [Abstract][Full Text] [Related]
9. Cell-mediated immunity against herpes simplex induction of cytotoxic T lymphocytes.
Lawman MJ; Rouse BT; Courtney RJ; Walker RD
Infect Immun; 1980 Jan; 27(1):133-9. PubMed ID: 6244225
[TBL] [Abstract][Full Text] [Related]
10. Transcutaneous immunisation with herpes simplex virus stimulates immunity in mice.
El-Ghorr AA; Williams RM; Heap C; Norval M
FEMS Immunol Med Microbiol; 2000 Dec; 29(4):255-61. PubMed ID: 11118905
[TBL] [Abstract][Full Text] [Related]
11. Preparation and efficacy of antiherpes type 1 and 2 subunit vaccines.
Kavaklova L; Dundarov S; Andonov P; Bakalov B; Dundarova D; Brodvarova I
Acta Virol; 1986 Sep; 30(5):402-10. PubMed ID: 2878588
[TBL] [Abstract][Full Text] [Related]
12. A novel strategy for converting recombinant viral protein into high immunogenic antigen.
Hinuma S; Hazama M; Mayumi A; Fujisawa Y
FEBS Lett; 1991 Aug; 288(1-2):138-42. PubMed ID: 1652468
[TBL] [Abstract][Full Text] [Related]
13. Passive transfer of anti-herpes simplex virus type 2 monoclonal and polyclonal antibodies protect against herpes simplex virus type 1-induced but not herpes simplex virus type 2-induced stromal keratitis.
Ritchie MH; Oakes JE; Lausch RN
Invest Ophthalmol Vis Sci; 1993 Jul; 34(8):2460-8. PubMed ID: 8392037
[TBL] [Abstract][Full Text] [Related]
14. Antibody reactivity with Skinner HSV vaccine.
Muniu EM; Durham J; Shariff D; Hartley CE; Fuller A; Melling J; Wiblin C; Wilkins G; Buchan A; Skinner GR
Med Microbiol Immunol; 1987; 176(6):315-27. PubMed ID: 2828898
[TBL] [Abstract][Full Text] [Related]
15. The mechanisms of antiviral immunity induced by a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: clearance of local infection.
Martin S; Rouse BT
J Immunol; 1987 May; 138(10):3431-7. PubMed ID: 3033075
[TBL] [Abstract][Full Text] [Related]
16. Viral isolation and systemic immune responses after intracameral inoculation of herpes simplex virus type 1 in Igh-1-disparate congenic murine strains.
Hemady R; Tauber J; Ihley TM; Opremcak EM; Foster CS
Invest Ophthalmol Vis Sci; 1990 Nov; 31(11):2335-41. PubMed ID: 2173686
[TBL] [Abstract][Full Text] [Related]
17. Antibodies against varicella-zoster virus and herpes simplex virus deoxythymidine kinase in heterologous infections.
Källander CF; Torfason EG; Olding-Stenkvist E; Sundqvist VA; Diderholm H; Gronowitz JS
J Med Virol; 1989 May; 28(1):30-7. PubMed ID: 2542443
[TBL] [Abstract][Full Text] [Related]
18. Antigen-presenting liposomes are effective in treatment of recurrent herpes simplex virus genitalis in guinea pigs.
Ho RJ; Burke RL; Merigan TC
J Virol; 1989 Jul; 63(7):2951-8. PubMed ID: 2542605
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of a herpes simplex subunit vaccine.
Cappel R; Sprecher S; De Cuyper F; De Braekeleer J
J Med Virol; 1985 Jun; 16(2):137-45. PubMed ID: 2989419
[TBL] [Abstract][Full Text] [Related]
20. Antibody responses and protection in mice immunized with herpes simplex virus type 1 antigen immune-stimulating complex preparations.
Ertürk M; Jennings R; Hockley D; Potter CW
J Gen Virol; 1989 Aug; 70 ( Pt 8)():2149-55. PubMed ID: 2769234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
